Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Chronic Obstructive Pulmonary Disease (COPD) · Non-Small Cell Lung Cancer

AstraZeneca

AstraZeneca AB

AstraZeneca clinical programs — 249 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB HQ
79,242 Employees
EMA registrant Type
Company details
Status
Public
HQ
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB
Employees
79,242
Programs
249
Drugs
238
Patents
2
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

AstraZeneca projects

249 ClinicalTrials.gov programs sponsored by AstraZeneca.

AstraZeneca has 249 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

249 programs

Clinical programs

Page 3 of 6

  1. D967RC00001

    AstraZeneca AB

    Early stage HER2-positive breast cancer (T stage >= T3, lymph node positive, or inflammatory)

    phase 3 small molecule active

    1 trial

  2. D967SC00001

    AstraZeneca AB

    Unresectable, locally advanced, or metastatic Non-Small Cell Lung Cancer with HER2 exon 19 or 20 mutations

    phase 3 small molecule active

    1 trial

  3. D967UC00001

    AstraZeneca AB

    HER2-positive metastatic breast cancer

    phase 3 small molecule active

    1 trial

  4. D9722C00001

    AstraZeneca AB

    Advanced Breast Cancer

    phase 3 small molecule active

    1 trial

  5. D9723C00001

    AstraZeneca AB

    Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

    phase 3 small molecule active

    1 trial

  6. D9727C00001

    AstraZeneca AB

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  7. D9802C00001

    AstraZeneca AB

    Gastric cancer, Advanced/Metastatic Gastric cancer, Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

    phase 3 small molecule active

    1 trial

  8. DANUBE/D419BC00001

    AstraZeneca AB

    Adult patients (age ≥18 years) with histologically or cytologically documented transitional cell carcinoma (transitional cell and mixed transitional/non transitional cell histologies) of the urothelium (including renal pelvis, ureters, urinary bladder, and urethra), unresectable Stage IV, and who are chemotherapy-naïve.

    phase 3 small molecule active

    1 trial

  9. DESTINYEndometrial01

    AstraZeneca AB

    HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer

    phase 3 small molecule active

    1 trial

  10. DUO-O/D081RC00001

    AstraZeneca AB

    Newly diagnosed advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian or primary peritoneal cancer

    phase 3 small molecule active

    1 trial

  11. Datopotamab deruxtecan for Stage I-III Triple-negative Bre…

    AstraZeneca AB

    Stage I-III Triple-negative Breast Cancer with residual invasive disease after neoadjuvant systemic therapy.

    phase 3 small molecule active

    1 trial

  12. Datopotamab deruxtecan, DOCETAXEL

    AstraZeneca AB

    TROP2 NMR-positive advanced or metastatic non-squamous non-small cell lung cancer without actionable genomic alterations.

    phase 3 small molecule active

    1 trial

  13. EMERALD-1

    AstraZeneca AB

    Locoregional Hepatocellular Carcinoma (HCC)

    phase 3 small molecule active

    1 trial

  14. GEMCITABINE for Patients with histologically or…

    AstraZeneca AB

    Patients with histologically or cytologically documented muscle-invasive transitional cell carcinoma (TCC) of the bladder

    phase 3 small molecule active

    1 trial

  15. IRIS, D3466C00001

    AstraZeneca AB

    Active Proliferative Lupus Nephritis

    phase 3 small molecule active

    1 trial

  16. JOURNEY

    AstraZeneca AB

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule active

    1 trial

  17. KOMET D134BC00001

    AstraZeneca AB

    Neurofibromatosis Type 1 (NF1) with Symptomatic, Inoperable Plexiform Neurofibromas (PN).

    phase 3 small molecule active

    1 trial

  18. PACIFIC2/D933KC00001

    AstraZeneca AB

    Patients with Locally Advanced, Unresectable Non-small Cell Lung Cancer (Stage III)

    phase 3 small molecule active

    1 trial

  19. PROpel D081SC00001

    AstraZeneca AB

    Metastatic castration-resistant prostate cancer

    phase 3 small molecule active

    1 trial

  20. SOLO 1-D0818C00001

    AstraZeneca AB

    BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer

    phase 3 small molecule active

    1 trial

  21. Tezspire 210 mg solution for injection in pre-filled syringe

    AstraZeneca AB

    Severe Asthma

    phase 3 small molecule active

    1 trial

  22. Tezspire 210 mg solution for injection in pre-filled syringe

    AstraZeneca AB

    Chronic Rhinosinusitis with Nasal Polyposis

    phase 3 small molecule active

    1 trial

  23. Tozorakimab, Tozorakimab-placebo

    AstraZeneca AB

    Severe viral lung infections

    phase 3 small molecule active

    1 trial

  24. Tropion-Breast05

    AstraZeneca AB

    Triple-negative Breast Cancer

    phase 3 small molecule active

    1 trial

  25. AZD0292, Placebo for AZD0292

    AstraZeneca AB

    Bronchiectasis with chronic pseudomonas aeruginosa colonization

    phase 2 small molecule active

    1 trial

  26. AZD0486, AZD0486

    AstraZeneca AB

    Relapsed or Refractory Non-Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  27. AZD1163 Placebo, AZD1163

    AstraZeneca AB

    Rheumatoid arthritis

    phase 2 small molecule active

    1 trial

  28. AZD2962, AZD2962

    AstraZeneca AB

    Myelodysplastic syndromes, Dysplastic chronic myelomonocytic leukaemia

    phase 2 small molecule active

    1 trial

  29. AZD3632, AZD3632

    AstraZeneca AB

    Relapsed or refractory acute leukaemia or Myelodysplastic Syndromes with HOX overexpression genotypes

    phase 2 small molecule active

    1 trial

  30. AZD4360

    AstraZeneca AB

    Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  31. AZD4512

    AstraZeneca AB

    Non-Hodgkin lymphoma (NHL)

    phase 2 small molecule active

    1 trial

  32. AZD4512

    AstraZeneca AB

    B-cell acute lymphoblastic leukemia (B-ALL)

    phase 2 small molecule active

    1 trial

  33. AZD6738, Ceralasertib

    AstraZeneca AB

    Advanced Cancer Whose Tumours Contain Molecular Alterations

    phase 2 small molecule active

    1 trial

  34. AZD7789

    AstraZeneca AB

    Advanced or metastatic gastric and gastro-esophageal junction (GEJ) adenocarcinoma, Advanced or Metastatic Non-small Cell Lung Carcinoma, Advanced or Metastatic Solid Tumors

    phase 2 small molecule active

    1 trial

  35. AZD7798 Placebo, AZD7798

    AstraZeneca AB

    Crohn's Disease

    phase 2 small molecule active

    1 trial

  36. AZD9750, Saruparib

    AstraZeneca AB

    Metastatic Prostate Cancer

    phase 2 small molecule active

    1 trial

  37. AZD9793

    AstraZeneca AB

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  38. CLARITY-PT01

    AstraZeneca AB

    Gastric Cancer, Gastroesophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  39. CYCAD-1(D8470C00001)

    AstraZeneca AB

    Patients with ER+ HER2- advanced breast cancer and patients with high-grade serious ovarian cancer (HGSOC)

    phase 2 small molecule active

    1 trial

  40. D361FC00001

    AstraZeneca AB

    Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  41. D4190C00022

    AstraZeneca AB

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  42. D419EC00001

    AstraZeneca AB

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  43. D4880C00003

    AstraZeneca AB

    unresectable pleural or peritoneal malignant mesothelioma

    phase 2 small molecule active

    1 trial

  44. D5162C00048

    AstraZeneca AB

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  45. D516AC00003

    AstraZeneca AB

    Unresectable Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  46. D5336C00001

    AstraZeneca AB

    Triple Negative Breast Cancer

    phase 2 small molecule active

    1 trial

  47. D533AC00001

    AstraZeneca AB

    Unresectable or Advanced Melanoma

    phase 2 small molecule active

    1 trial

  48. D6132C00001

    AstraZeneca AB

    First-line patients with extensive disease small-cell lung cancer (SCLC)

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does AstraZeneca have?

249 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.